MAP2K7 and neoplasm: However, in tumor and normal cells expressing wild-type BRAF, these inhibitors have been found to promote BRAF dimerization, activation and binding to RAS-GTP, ultimately resulting in stimulation of MEK-ERK signaling and proliferative effects (3, 4).